ZVSA Stock Performance, Insider Transaction and News

ZVSA - ZyVersa Therapeutics, Inc.

Market Cap	4.02M	P/E	-	EPS this Y	98.60%	Ern Qtrly Grth	-
Income	-106.25M	Forward P/E	-	EPS next Y	-532.70%	50D Avg Chg	-41.00%
Sales	-	PEG	-	EPS past 5Y	-	200D Avg Chg	-95.00%
Dividend	N/A	Price/Book	0.02	EPS next 5Y	-	52W High Chg	-99.00%
Recommedations	2.00	Quick Ratio	0.31	Shares Outstanding	7.59M	52W Low Chg	6.00%
Insider Own	0.83%	ROA	-12.82%	Shares Float	7.50M	Beta	0.58
Inst Own	2.65%	ROE	-177.53%	Shares Shorted/Prior	460.79K/645.99K	Price	0.17
Gross Margin	-	Profit Margin	-	Avg. Volume	2,226,495	Target Price	8.00
Oper. Margin	-	Earnings Date	-	Volume	908,446	Change	-0.18%

Healthcare | Biotechnology | United States

About ZyVersa Therapeutics, Inc.

ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company engages in the development of VAR 200, a cholesterol efflux mediator, which is in Phase 2a clinical trial to the treatment of multiple renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic nephropathy; and IC 100, a monoclonal antibody inflammasome ASC inhibitor that is in preclinical stage for treatment of multitude of inflammatory diseases. ZyVersa Therapeutics, Inc. is headquartered in Weston, Florida.

ZyVersa Therapeutics, Inc. News

04/04/24	ZyVersa Therapeutics Highlights Published Data Demonstrating NLRP3 Inflammasome Inhibition Has Potential to Decrease Atherosclerotic Lesions in Patients with Diabetes
03/25/24	ZyVersa Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
03/18/24	ZyVersa Therapeutics Announces IRB Approval of Phase 2a Clinical Trial Protocol to Evaluate Cholesterol Efflux Mediator™ VAR 200 in Patients with Diabetic Kidney Disease
03/14/24	ZyVersa Therapeutics' CEO, Stephen C. Glover to Participate in a Panel Discussion Titled “Inflammation Illuminated,”at Benzinga’s Virtual Healthcare Summit 2024 on March 20, 2024
02/29/24	ZyVersa Therapeutics Generated Approximately $2.7 Million From Exercise of Warrants Following Excitement Around News That Inflammasome Inhibitors Have Potential to Effectively Treat Obesity
02/28/24	ZyVersa Therapeutics Highlights Data from Review Article Published in Nature Reinforcing IC 100’s Rationale for Inhibiting ASC and ASC Specks to Attenuate Damaging Inflammation Associated with Various Conditions, Including Obesity and Its Complications
02/22/24	ZyVersa Therapeutics Publishes New White Paper Detailing the Role of Inflammasomes and ASC Specks in Neurological Diseases, and Data Supporting Inflammasome ASC Inhibitor IC 100 as a Potential Therapeutic Option
02/14/24	ZyVersa Therapeutics Highlights Review Article Substantiating That Inflammasome Activation Is Pathogenic in Multiple Neurological Diseases
02/07/24	ZyVersa Therapeutics' CEO, Stephen C. Glover to Present at the 2024 BIO CEO & Investor Conference to Provide Corporate Update and Discuss Key Milestones
01/31/24	ZyVersa Therapeutics Highlights Publication Indicating That Inflammasome NLRP3-Mediated Inflammation in Obese Children Leads to Insulin Resistance and Risk of Complications Such as Type 2 Diabetes
01/24/24	ZyVersa Therapeutics Announces Peer-Reviewed Article Supporting the Therapeutic Potential of Targeting ASC Specks During Progression of Alzheimer’s Disease
01/17/24	Why Is Inflammatory Disease-Focused ZyVersa Therapeutics Stock Trading Higher Today?
01/17/24	ZyVersa Therapeutics Highlights Peer-Reviewed Article Linking Inflammasome Activation to Triple-Negative Breast Cancer Brain Metastasis
01/10/24	ZyVersa Therapeutics’ CEO, Stephen C. Glover, Featured on Benzinga All Access
01/04/24	ZyVersa Therapeutics Announces Equity Research Coverage Initiated by Noble Capital Markets
01/03/24	ZyVersa Therapeutics CEO, Stephen C. Glover, Issues Letter to Shareholders Providing Outlook for 2024
12/18/23	ZyVersa Therapeutics’ CEO, Stephen C. Glover, to Participate in BIO Partnering @ JPM During “J.P. Morgan Week 2024”
12/14/23	ZyVersa Therapeutics Engages CRO, George Clinical, for Phase 2a Clinical Trial for Cholesterol Efflux Mediator VAR 200
12/07/23	ZyVersa Therapeutics Announces Publication Demonstrating That Plasma Levels of NLRP3 Inflammasomes Correlate with Progression of Diabetic Kidney Disease in Patients with Type 2 Diabetes
12/06/23	ZyVersa Therapeutics, Inc. Announces Pricing of $5.0 Million Public Offering

ZVSA Chatroom

tradethehalt Posted - 5 hours ago

$ZVSA trade halt (T1) was alerted to our Members at 7:50pm EDT. Halt price: $0.58 Vol: 409.02K.

HaltTradeAlert Posted - 6 hours ago

$ZVSA Halt Time: 19:50:00 Issue Symbol: ZVSA Reason Code: T1 Last Price: $0.61 Market Cap: $4613877 Volume: 394949.0 Relative Volume: 1.22 Shares Float: 7594860 Our members get this alert real time and sent to their phone just like a text. Members also get free real time news catalyst alerts! Go to our website and join our community for free! www.HaltTradeAlert.com

pmcgee5029 Posted - 9 hours ago

$ZVSA I made another purchase today!

VisionBlue Posted - 10 hours ago

$ZVSA $4.63M market cap.. per Fidelity. Does that even resemble the value of their Inflammasome Platform? Just like a baseball resembles the moon. Full moon coming..

bubbybubster Posted - 16 hours ago

$ZVSA anybody know if fractional shares will be rounded up in the RS?

Bigmoney4me Posted - 1 day ago

$ABVC $AIRE $ZVSA $DRMA hey ya’ll… $CYCC and cancer reveal hold for 100 (maybe!)

John_D_Stockefeller Posted - 1 day ago

$ZVSA Dow closed red. This is solidly green. Going to the pharmacy for some heart pills. This might be the big one.

Rampart1 Posted - 1 day ago

$ZVSA nice bounce kinda. Things are way oversold.

RollingDollar Posted - 1 day ago

$ZVSA

Unknmarket Posted - 1 day ago

🦦

John_D_Stockefeller Posted - 2 days ago

$ZVSA Glover must be really inept…..bought in here hoping for a play out like $AMAM. Glover might just be content with a nice view from his office, golf on company time, 5-Michelson lunches, and a never-ending, big paycheck. IMO.

VisionBlue Posted - 2 days ago

$ZVSA they know the price of every thing, and the value of nothing. buy value..

__jloveee Posted - 2 days ago

vue556 Posted - 2 days ago

Gt015460 Posted - 2 days ago

TravisBking87 Posted - 2 days ago

$ZVSA

moliva Posted - 2 days ago

Earth4thewin Posted - 2 days ago

$ZVSA seems like it just keeps hitting new all time lows , this is the pits 😔

yada010 Posted - 3 days ago

$ZVSA time to swing the PIPE, Glover

VisionBlue Posted - 3 days ago

$ZVSA let's see it close .61-.62

Earth4thewin Posted - 3 days ago

$ZVSA new all time lows today, 🙄 Now Below 2 cents pre the 35 for 1 reverse split and offering they did on December 4th of last year,wonder how low it will go after the next 10 for 1 reverse split at the end of this month? I imagine Stephen Glover will want yet another offering after he finishes the next reverse split like he did back in December?